BioCryst Pharmaceuticals Inc (BCRX) Dividend History

Company News

• BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

  BioCryst Pharmaceuticals will present new data on its oral, once-daily drug ORLADEYO for the treatment of hereditary angioedema at the EAACI meeting in June 2025.

  GlobeNewswire Inc.
• BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

  BioCryst Pharmaceuticals presented new real-world evidence showing significant and sustained reductions in hereditary angioedema (HAE) attack rates in adolescents and people with severe HAE following initiation of their oral therapy ORLADEYO (berotralstat).

  GlobeNewswire Inc.
• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  BioCryst Pharmaceuticals, a global biotechnology company, announced that it has granted restricted stock units (RSUs) covering 48,000 shares to seven newly-hired employees as inducements to join the company. The RSUs will vest over four years, subject to the employees' continued service.

  GlobeNewswire Inc.
• BioCryst to Present at Upcoming Investor Conferences

  BioCryst Pharmaceuticals, a global biotechnology company, announced plans to present at several upcoming conferences and report its first quarter 2025 financial results. The company is focused on developing treatments for hereditary angioedema and other rare diseases.

  GlobeNewswire Inc.
• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  BioCryst Pharmaceuticals granted restricted stock units to 10 newly-hired employees, with the RSUs vesting over four years. The company is a global biotechnology firm focused on rare diseases.

  GlobeNewswire Inc.